Autosomal dominant polycystic kidney disease

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Simms, Roslyn J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCYSTIN 1; PRAVASTATIN; SOMATOSTATIN DERIVATIVE; TOLVAPTAN; BENZAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASOPRESSIN RECEPTOR ANTAGONIST;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; ECHOGRAPHY; FAMILY HISTORY; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; INTRACELLULAR SIGNALING; KIDNEY DONOR; KIDNEY POLYCYSTIC DISEASE; PATIENT MONITORING; PATIENT REFERRAL; PKD1 GENE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; COMPLICATION; DISEASE COURSE; GENETICS; HYPERTENSION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RISK FACTORS;

EID: 84960157420     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i679     Document Type: Review

References (75)

1. Chapman AB, Devuyst O, Eckardt KU, et al. Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015;88:17-27. doi:10. 1038/ki.2015.59. 25786098.
2. Ong AC, Devuyst O, Knebelmann B, Walz G. ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 2015;385:1993-2002. doi:10.1016/S0140-6736(15)60907-2. 26090645.
3. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321-37. doi: 10.1146/annurev.med.60.101707.125712. 18947299.
4. Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology (Carlton) 2006;11:124-30. doi:10.1111/j.1440-1797.2006.00535.x. 16669974.
5. Dalgaard OZ. Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med Scand Suppl 1957;328:1-255.13469269.
6. Simon P, Le Goff JY, Ang KS, Charasse C, Le Cacheux P, Cam G. Données épidémiologiques, cliniques et pronostiques de la maladie polykystique autosomique dominante dans une région française.Nephrologie 1996;17:123-30.8838759.
7. Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D. Polycystic kidney disease re-evaluated: a population-based study. Q J Med 1991;79:477-85.1946928.
8. Higashihara E, Nutahara K, Kojima M, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 1998;80:421-7. doi: 10.1159/000045214. 9832641.
9. The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell 1994;77:881-94. doi:10.1016/0092-8674(94)90137-6. 8004675.
10. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301. doi:10.1016/S0140-6736(07)60601-1. 17434405.
11. Mochizuki T, Wu G, Hayashi T, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996;272:1339-42. doi:10.1126/science. 272.5266.1339. 8650545.
12. Chang MY, Ong AC. New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol 2013;76:524-35.23594398.
13. Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int 2015;88:699-710. doi:10.1038/ki.2015.207. 26200945.
14. Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013;24:1006-13. doi:10.1681/ASN. 2012070650. 23431072.
15. Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group.Lancet 1999;353:103-7. doi:10.1016/S0140-6736(98)03495-3. 10023895.
16. Thong KM, Ong AC. The natural history of autosomal dominant polycystic kidney disease: 30-year experience from a single centre. QJM 2013;106:639-46. doi:10.1093/qjmed/hct082. 23587574.
17. Lantinga MA, Drenth JP, Gevers TJ. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant 2015;30:744-51. doi:10.1093/ndt/gfu227. 24950937.
18. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12:194-200.11134267.
19. Chapman AB, Schrier RW. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991;11:653-60.1767138.
20. Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-80. doi:10.1038/ki.1990.330. 2074659.
21. Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-9. doi:10.1038/ki.1992.195. 1614046.
22. Cornec-Le Gall E, Audrézet MP, Rousseau A, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 2015;ASN.2015010016.26150605.
23. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010;17:153-63. doi:10.1053/j.ackd. 2010.01.001. 20219618.
24. Gansevoort RT, Meijer E, Chapman AB, et al. TEMPO 3:4 Investigators. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 2015;gfv422. doi:10.1093/ndt/gfv422. 26681730.
25. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;5:1349-54.7894001.
26. Shaw C, Simms RJ, Pitcher D, Sandford R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transplant 2014;29:1910-8. doi:10.1093/ndt/gfu087. 24737444.
27. Bae KT, Zhu F, Chapman AB, et al. Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006;1:64-9. doi:10.2215/CJN.00080605. 17699192.
28. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997;26:1282-6.9362373.
29. Hogan MC, Abebe K, Torres VE, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol 2015;13:155-64.e6. doi:10.1016/j.cgh.2014.07.051. 25111236.
30. Torres VE, Rastogi S, King BF, Stanson AW, Gross JB Jr., , Nogorney DM. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994;5:1186-92.7873728.
31. Alpern MB, Dorfman RE, Gross BH, Gottlieb CA, Sandler MA. Seminal vesicle cysts: association with adult polycystic kidney disease. Radiology 1991;180:79-80. doi:10.1148/radiology.180.1.2052727. 2052727.
32. Schievink WI, Huston J 3rd, , Torres VE, Marsh WR. Intracranial cysts in autosomal dominant polycystic kidney disease. J Neurosurg 1995;83:1004-7. doi:10.3171/jns.1995. 83.6.1004. 7490613.
33. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-7.9259356.
34. Perrone RD, Abebe KZ, Schrier RW, et al. HALT PKD Study Group. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:2508-15. doi:10.2215/CJN.04610511. 21903983.
35. Almeida EA, Oliveira EI, Lopes JA, Almeida AG, Prata MM. Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2006;47:587-92. doi:10.1053/j.ajkd.2005.12. 023. 16564936.
36. Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA. Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 1988;319:907-12. doi: 10.1056/NEJM198810063191404. 3419455.
37. Qian Q, Hartman RP, King BF, Torres VE. Increased occurrence of pericardial effusion in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007;2:1223-7. doi:10.2215/CJN.01920507. 17928471.
38. Irazabal MV, Huston J 3rd, , Kubly V, et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:1274-85. doi:10.2215/CJN. 09731110. 21551026.
39. Xu HW, Yu SQ, Mei CL, Li MH. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011;42:204-6. doi:10.1161/STROKEAHA.110.578740. 21164130.
40. Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2002;13:269-76.11752048.
41. Chapman Jr., Hilson AJ. Polycystic kidneys and abdominal aortic aneurysms. Lancet 1980;1:646-7. doi:10.1016/S0140-6736(80)91135-6. 6102642.
42. Bailey MA, Griffin KJ, Windle AL, Lines SW, Scott DJ. Cysts and swellings: a systematic review of the association between polycystic kidney disease and abdominal aortic aneurysm. Ann Vasc Surg 2013;27:123-8. doi:10.1016/j.avsg.2012.05.013. 23088808.
43. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant 2014;29:247-54. doi:10.1093/ndt/gft437. 24215018.
44. Morris-Stiff G, Coles G, Moore R, Jurewicz A, Lord R. Abdominal wall hernia in autosomal dominant polycystic kidney disease. Br J Surg 1997;84:615-7. doi:10.1002/bjs. 1800840509. 9171744.
45. Sharp CK, Zeligman BE, Johnson AM, Duley I, Gabow PA. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. Am J Kidney Dis 1999;34:863-8. doi:10.1016/S0272-6386(99)70043-0. 10561142.
46. Moua T, Zand L, Hartman RP, et al. Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease. PLoS One 2014;9:e93674. doi:10. 1371/journal.pone.0093674. 24747723.
47. Chapman AB, Torres VE, Perrone RD, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5:102-9. doi:10.2215/CJN. 04310709. 20089507.
48. Persu A, Duyme M, Pirson Y, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD.Kidney Int 2004;66:2132-6. doi:10.1111/j.1523-1755. 2004.66003.x. 15569302.
49. Simms RJ, Thong KM, Dworschak GC, Ong AC. Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2015;gfv299. doi:10.1093/ndt/gfv299. 26268712.
50. Suwabe T, Ubara Y, Mise K, et al. Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol 2013;14:179. doi:10.1186/1471-2369-14-179. 23978051.
51. Tong A, Rangan GK, Ruospo M, et al. A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrol Dial Transplant 2015;30:790-800. doi:10.1093/ndt/gfv010. 25637642.
52. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009;20:205-12. doi:10.1681/ASN.2008050507. 18945943.
53. Pei Y, Hwang YH, Conklin J, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2015;26:746-53. doi:10.1681/ASN. 2014030297. 25074509.
54. Simms RJ, Travis DL, Durkie M, Wilson G, Dalton A, Ong AC. Genetic testing in the assessment of living related kidney donors at risk of autosomal dominant polycystic kidney disease. Transplantation 2015;99:1023-9. doi:10.1097/TP.0000000000000466. 25340609.
55. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis 2015;S0272-6386(15)01216-0.26530876.
56. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008;74:1192-6. doi:10.1038/ki.2008.397. 18716604.
57. Simms RJ, Ong AC. How simple are 'simple renal cysts'?Nephrol Dial Transplant 2014;29(Suppl 4):iv106-12. doi:10.1093/ndt/gfu106. 25165175.
58. Nahm AM, Ritz E. Acquired renal cysts. Nephrol Dial Transplant 2001;16:1506-8. doi:10. 1093/ndt/16.7.1506. 11427653.
59. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998;13:624-8. doi:10.1177/088307389801301206. 9881533.
60. Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-A contiguous gene syndrome. Nat Genet 1994;8:328-32. doi:10.1038/ng1294-328. 7894481.
61. Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management-A KDIGO consensus report. Kidney Int 2015;88:676-83. doi:10.1038/ki.2015.28. 25738250.
62. Sweeney WE Jr., , Avner ED. Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol 2011;26:675-92. doi:10.1007/s00467-010-1656-1. 21046169.
63. Feather SA, Woolf AS, Donnai D, Malcolm S, Winter RM. The oral-facial-digital syndrome type 1 (OFD1), a cause of polycystic kidney disease and associated malformations, maps to Xp22.2-Xp22.3. Hum Mol Genet 1997;6:1163-7. doi:10.1093/hmg/6.7.1163. 9215688.
64. Thauvin-Robinet C, Cossée M, Cormier-Daire V, et al. Clinical, molecular, and genotype-phenotype correlation studies from 25 cases of oral-facial-digital syndrome type 1: a French and Belgian collaborative study. J Med Genet 2006;43:54-61. doi:10.1136/jmg.2004.027672. 16397067.
65. Di Salvo DN, Park J, Laing FC. Lithium nephropathy: unique sonographic findings. J Ultrasound Med 2012;31:637-44.22441921.
66. Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009;20:1833-8. doi:10.1681/ASN. 2009020162. 19443633.
67. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:820-9. doi:10.1056/NEJMoa0907419. 20581391.
68. Torres VE, Chapman AB, Devuyst O, et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18. doi:10.1056/NEJMoa1205511. 23121377.
69. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:830-40. doi:10.1056/NEJMoa1003491. 20581392.
70. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-57. doi:10.2215/CJN.00330705. 17699202.
71. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015;26:160-72. doi:10.1681/ASN.2013101138. 24904092.
72. Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database Syst Rev 2015;7:CD010294.26171904.
73. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12. doi:10.7326/0003-4819-150-9-200905050-00006. 19414839.
74. Schrier RW, Abebe KZ, Perrone RD, et al. HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014;371:2255-66. doi:10.1056/NEJMoa1402685. 25399733.
75. Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2014;9:889-96. doi:10.2215/CJN. 08350813. 24721893.